Pyxis Oncology (PYXS)
NASDAQ:PYXS
Want to see PYXS full AI Analyst Report?
Top Page
Pyxis Oncology
(NASDAQ:PYXS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▲(20.48% Upside)
Action:ReiteratedDate:04/23/26
The score is held back primarily by weak financial performance—large ongoing losses, significant cash burn, and effectively no material recurring revenue streams—despite manageable leverage. Technicals are moderately supportive in the short term (positive MACD and above key short-term averages) but are tempered by overbought signals and a still-weak longer-term trend. Valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Regulatory alignment for pivotal trial
FDA alignment on a pivotal MICVO monotherapy trial is a durable reduce-in-regulatory-uncertainty outcome. It clarifies trial endpoints and design, improving predictability of development, making future regulatory interactions and partner or investor decisions more efficient over the next 2–6 months and beyond.
Negative Factors
Significant persistent cash burn
Sustained negative free cash flow (~-$63.5M in 2025) is a structural pressure that erodes liquidity and equity over time. Persistent burn forces recurring financing, increases dilution risk and constrains strategic optionality if clinical timelines slip or expected partnerships do not materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment for pivotal trial
FDA alignment on a pivotal MICVO monotherapy trial is a durable reduce-in-regulatory-uncertainty outcome. It clarifies trial endpoints and design, improving predictability of development, making future regulatory interactions and partner or investor decisions more efficient over the next 2–6 months and beyond.
Read all positive factors
Pyxis Oncology (PYXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.58M
Dividend YieldN/A
Average Volume (3M)757.02K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth-14.17%
EPS Growth0.94%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding62,831,245
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue8.21
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$6.20Price Target Upside273.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$58.33K
Pyxis Oncology Business Overview & Revenue Model
Company Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-...
How the Company Makes Money
Pyxis Oncology is a clinical-stage company and does not have a disclosed commercial product portfolio generating recurring product sales. As a result, revenue—when present—is primarily driven by non-recurring or development-stage sources rather th...
Pyxis Oncology Key Performance Indicators (KPIs)
Pyxis Oncology Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.86M | 16.15M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.47M | 15.67M | 0.00 | 0.00 | 0.00 |
| EBITDA | -79.91M | -65.51M | -80.27M | -122.77M | -69.07M |
| Net Income | -79.62M | -77.33M | -73.79M | -120.72M | -75.97M |
Balance Sheet | |||||
| Total Assets | 91.52M | 157.18M | 173.73M | 211.38M | 280.02M |
| Cash, Cash Equivalents and Short-Term Investments | 66.86M | 126.93M | 119.30M | 179.29M | 274.74M |
| Total Debt | 18.67M | 20.20M | 21.33M | 18.92M | 165.00K |
| Total Liabilities | 38.11M | 36.43M | 48.02M | 50.55M | 18.71M |
| Stockholders Equity | 53.41M | 120.75M | 125.70M | 160.82M | 261.31M |
Cash Flow | |||||
| Free Cash Flow | -63.51M | -57.91M | -77.44M | -95.73M | -35.87M |
| Operating Cash Flow | -63.50M | -57.67M | -70.71M | -89.33M | -35.33M |
| Investing Cash Flow | 58.86M | 8.15M | -104.85M | -6.40M | -590.00K |
| Financing Cash Flow | 594.00K | 59.33M | 5.93M | 183.00K | 304.04M |
Pyxis Oncology Technical Analysis
Neutral
1.66
Price Trends
1.49
Positive
2.02
Negative
2.14
Negative
Market Momentum
0.06
Negative
58.61
Neutral
65.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Neutral. The current price of 1.66 is above the 20-day moving average (MA) of 1.51, above the 50-day MA of 1.49, and below the 200-day MA of 2.14, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 58.61 is Neutral, neither overbought nor oversold. The STOCH value of 65.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PYXS.
Pyxis Oncology Risk Analysis
Pyxis Oncology disclosed 83 risk factors in its most recent earnings report. Pyxis Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pyxis Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $215.30M | -1.25 | -30.02% | ― | ― | 15.26% | |
53 Neutral | $107.00M | 4.86 | -243.73% | ― | ― | 60.38% | |
52 Neutral | $235.51M | -5.63 | -131.80% | ― | ― | -19.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $201.45M | -3.95 | -977.67% | ― | ― | 42.43% | |
47 Neutral | $110.58M | -0.99 | -101.77% | ― | -14.17% | 0.94% |
* Healthcare Sector Average
PYXS
Pyxis Oncology
1.76
0.57
47.90%
NKTX
Nkarta
3.02
1.04
52.53%
GLSI
Greenwich LifeSciences
21.98
12.12
122.92%
ELTX
Elicio Therapeutics
10.77
5.36
99.08%
BMEA
Biomea Fusion
1.48
-0.52
-26.00%
NVCT
Nuvectis Pharma
8.89
-0.48
-5.12%
Pyxis Oncology Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
Positive
Mar 23, 2026
Pyxis Oncology reported a series of clinical and corporate milestones alongside its fourth quarter and full-year 2025 results, released on March 23, 2026, highlighting progress in its MICVO program for recurrent/metastatic head and neck squamous c...
Business Operations and StrategyExecutive/Board Changes
Pyxis Oncology Announces Interim CEO Amid Leadership Transition
Neutral
Feb 6, 2026
On February 2, 2026, Pyxis Oncology implemented a leadership transition in which Lara S. Sullivan, M.D., stepped down as president, chief executive officer and chief medical officer, and board member Thomas Civik was appointed interim chief execut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.